
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is well-positioned to see continued success and growth in the coming years due to its strong product pipeline, recent NDA resubmission for relacorilant, and successful pharmacy transition for their flagship product Korlym. Financially, the company's strong sales growth in Korlym and early physician adoption of their recently approved drug, Lifyroli, suggest potential for significant revenue growth in the future. Risks to this outlook include potential issues with commercialization and regulatory approval, as well as any potential legal or intellectual property challenges.
Bears say
Corcept Therapeutics is facing potential challenges as its current flagship product Korlym, which accounts for the majority of its revenue, approaches generic competition in 2024. Additionally, its pipeline compounds are still in clinical trials and may not see success in the market, leading to limited future revenue growth. This, coupled with the fact that the company has a history of high operating expenses and net losses, paints a negative outlook for its stock.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares